Accelerated hemodiafiltration for severe diquat poisoning
Part of Kidney & urinary clinical trials.
This trial tests a faster type of blood filtering (hemodiafiltration) for people who have taken a large amount of diquat, a toxic weedkiller. The goal is to see if this treatment helps remove the poison from the blood quickly and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have swallowed diquat liquid (not inhaled or touched skin).
- You must get to the emergency room within 48 hours of taking the poison.
- Your blood level of diquat must be very high (at least 1,000 ng/mL).
- You cannot have taken other poisons at the same time.
- You must not have had kidney dialysis or a kidney transplant in the recent past.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if starting a type of blood cleaning (CVVHDF) more quickly after a filtering step (hemoperfusion) works better than waiting a bit longer in people with severe diquat poisoning. It aims to find the safest and most effective way to remove the poison from your blood.
This trial checks how accurate a new test kit is at measuring diquat (a weed killer) in blood samples. If you have been exposed to diquat, your leftover blood sample may be used to see if this new method works well.
This trial compares two types of dialysis (hemodialysis and hemodiafiltration) to see which is better at removing waste from the blood in ICU patients with sudden kidney failure. It may help doctors choose the best treatment for you.
This trial tests a blood-filtering device (hemadsorption) to help remove drugs from the body faster in people who are in the ICU after an overdose of certain sedatives or antidepressants, especially if they have liver or kidney problems.
This trial tests a special blood-filtering treatment (hemoperfusion) for people with advanced kidney disease on regular dialysis. It aims to remove harmful substances that standard dialysis may not fully clear.
This trial tests whether a faster rate of fluid removal during dialysis can help hospitalized patients with end-stage kidney disease who have severe fluid buildup. It aims to reduce fluid congestion and improve outcomes.
Hear when a new Diquat Poisoning trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.